@Mineralystx Mineralys Therapeutics

Mineralys Therapeutics posts on X about $mlys, financial, in the, heart the most. They currently have [---] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: [--] #

• [--] Week [--] -12%
• [--] Month [---] +154%
• [--] Months [---] +64%

Mentions: [--] #

Followers: [---] #

• [--] Week [---] -0.70%
• [--] Month [---] +2.20%
• [--] Months [---] +12%

CreatorRank: undefined #

Social Influence

Social category influence stocks 80.56% finance 8.33%

Social topic influence $mlys 66.67%, financial 11.11%, in the 11.11%, heart 8.33%, update 5.56%, for the 5.56%, the american 5.56%, we are 5.56%, the most 5.56%, closed 5.56%

Top accounts mentioned or mentioned by @asnkidney @jamacurrent @nejm @fwpharma @jama @blackgirlsrun @jamanetwork

Top assets mentioned Mineralys Therapeutics, Inc. (MLYS)

Top Social Posts

Top posts by engagements in the last [--] hours

"Today we reported financial results for the third quarter ending September [--] [----] and provided a corporate update. Learn more: #Hypertension #CKD #OSA #CardioRenalMetabolic #CVRM $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial"
X Link 2025-11-10T21:06Z [---] followers, [--] engagements

"Today we issued a corporate update highlighting several recent and upcoming clinical & regulatory milestones. Mineralys' management team will also participate in the LifeSci Partners Corporate Access event taking place January 12-14 in San Francisco. $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/89/mineralys-therapeutics-provides-corporate-update-and https://ir.mineralystx.com/news-events/press-releases/detail/89/mineralys-therapeutics-provides-corporate-update-and"
X Link 2026-01-06T14:55Z [---] followers, [---] engagements

"This week is the American Heart Associations #HealthyWeightWeek. #Obesity & #hypertension often coexist and dysregulated aldosterone is frequently observed in patients with uncontrolled or treatment-resistant hypertension and in patients with obesity"
X Link 2026-01-20T15:53Z [---] followers, [---] engagements

"At Mineralys we are advancing lorundrostat a highly selective aldosterone synthase inhibitor designed to directly target aldosterone production and explore a more precise approach to blood pressure biology. #HTN #Obesity #CardiometabolicHealth #Aldosterone #BloodPressure"
X Link 2026-01-20T15:53Z [---] followers, [--] engagements

"Our CEO Jon Congleton spoke with @fwpharma about how Mineralys is reviving innovation in #hypertension by targeting aldosterone what differentiates the companys approach and where lorundrostat could play a role across cardiorenal and metabolic disease. Read the interview here: $MLYS https://firstwordpharma.com/story/7067623 https://firstwordpharma.com/story/7067623"
X Link 2026-01-22T17:29Z [---] followers, [--] engagements

"We will be sharing data from our pivotal Phase [--] Launch-HTN trial in a late-breaking session at #ESH2025 on Saturday May [--] from 10:00-11:00am CEST. Read our press release for additional details: $MLYS #hypertension #bloodpressure https://ir.mineralystx.com/news-events/press-releases/detail/71/mineralys-therapeutics-announces-late-breaking-presentation https://ir.mineralystx.com/news-events/press-releases/detail/71/mineralys-therapeutics-announces-late-breaking-presentation"
X Link 2025-05-20T12:27Z [---] followers, [---] engagements

"Our P3 Launch-HTN trial of lorundrostat - the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension - was featured in JAMAs inaugural Research of the Year article https://ir.mineralystx.com/news-events/press-releases/detail/88/mineralys-therapeutics-phase-3-launch-htn-trial-of Introducing JAMAs Research of the Year. Chosen by JAMA editors the inaugural roundup highlights [--] of the most impactful newsworthy and novel studies published in the journal over the past year. 🧵 #JAMAROTY25 🔗 https://t.co/zvpFrvH0Os"
X Link 2025-12-12T17:39Z [---] followers, [---] engagements

"In February we honor #HeartMonth as well as #CardiovascularProfessionalsWeek. Mineralys celebrates the dedicated individuals working tirelessly on the prevention diagnosis treatment and rehabilitation of heart and vascular diseases"
X Link 2026-02-11T17:23Z [---] followers, [--] engagements

"Detailed results from the pivotal P3 Launch-HTN trial were published today in @JAMA reinforcing lorundrostats efficacy in a real-world setting. Read our press release to learn more: #bloodpressure $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american"
X Link 2025-06-30T15:27Z [---] followers, [--] engagements

"We will report our financial results from the second quarter ended June [--] [----] after the financial markets close on Tuesday August [--] [----]. Register for the conference call here: #Hypertension $MLYS https://viavid.webcasts.com/starthere.jspei=1726467&tp_key=ed64a9a274 https://viavid.webcasts.com/starthere.jspei=1726467&tp_key=ed64a9a274"
X Link 2025-08-05T11:10Z [---] followers, [---] engagements

"If youre attending #AHA25 stop by & connect with our Med Affairs team to learn more about our focus on aldosterone biology in CRM diseases. 📍Booth #4216 And join us Saturday in Heart Theater [--] for a discussion on the unmet need in uncontrolled #hypertension. Hope to see you"
X Link 2025-11-07T19:02Z [---] followers, [--] engagements

"We shared data from the P2 Explore-CKD trial during a late-breaking oral presentation at #KidneyWk. Parallel reductions in #SBP & albuminuria underscore lorundrostat's potential to improve cardio-renal outcomes in this high-risk population. http://ir.mineralystx.com/news-events/ http://ir.mineralystx.com/news-events/"
X Link 2025-11-07T23:37Z [---] followers, [---] engagements

"2025 was an exciting year for Mineralys We are grateful to everyone who contributed to our journey to advance Lorundrostats development in #HTN #CKD and #OSA"
X Link 2025-12-31T12:04Z [---] followers, [--] engagements

"Our team was in #Detroit w/ @blackgirlsrun & Dr. John Flack who discussed health equity & how black women can prioritize healthy living. Mineralys is focused on improving outcomes for people w/ #hypertension including high-risk populations & was honored to be part of this event"
X Link 2025-10-29T14:10Z [---] followers, [---] engagements

"#Hypertension remains the leading modifiable risk factor for #CVD despite decades of therapeutic efforts. Aldosterone dysregulation is increasingly recognized as a missing piece of the puzzle. Read: $MLYS https://www.statnews.com/sponsor/2025/09/22/can-a-new-class-of-drugs-finally-control-hypertension-in-millions-of-patients/ https://www.statnews.com/sponsor/2025/09/22/can-a-new-class-of-drugs-finally-control-hypertension-in-millions-of-patients/"
X Link 2025-10-30T18:24Z [---] followers, [---] engagements

"We will report our financial results from the third quarter after the financial markets close on Monday November [--] [----]. Register for the conference call here: #Hypertension $MLYS https://viavid.webcasts.com/starthere.jspei=1736067&tp_key=a4874c7d90 https://viavid.webcasts.com/starthere.jspei=1736067&tp_key=a4874c7d90"
X Link 2025-11-03T21:09Z [---] followers, [---] engagements

"We will be participating in fireside chats at three upcoming investor conferences. Details and webcast links can be found here: $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/84/mineralys-therapeutics-to-participate-in-upcoming-investor https://ir.mineralystx.com/news-events/press-releases/detail/84/mineralys-therapeutics-to-participate-in-upcoming-investor"
X Link 2025-11-06T19:34Z [---] followers, [---] engagements

"If youre in #Houston for @ASNKidney #KidneyWk join us tomorrow in Grand Ballroom C at the Convention Center to catch our #latebreaking presentation. We hope to see you there #Hypertension #CKD #KidneyCare"
X Link 2025-11-06T21:23Z [---] followers, [---] engagements

"In addition our pivotal Phase [--] Launch-HTN trial was featured in the Best of the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine (NEJM) session. @JAMA_current #Hypertension #CKD #CardioRenalMetabolic $MLYS https://x.com/JAMA_current/status/1939705490914574601 In this pivotal phase [--] RCT lorundrostat lowered blood pressure in adults with uncontrolled or treatment-resistant #hypertension on multiple antihypertensive medications. https://t.co/jbHmK4SMSB https://t.co/7xPtmBMNZS https://x.com/JAMA_current/status/1939705490914574601 In this pivotal phase 3"
X Link 2025-11-07T23:37Z [---] followers, [---] engagements

"February is American #HeartMonth ❤ Despite the availability of effective therapies for #hypertension treatment and control rates have stalled and related CV death rates in the U.S. have nearly doubled in [--] years. At Mineralys were advancing science to change this trajectory. #KnowYourNumbers"
X Link 2026-02-04T14:15Z [---] followers, [--] engagements

"Today we announced that our pivotal Launch-HTN and Advance-HTN trials of lorundrostat in uncontrolled or resistant #hypertension both met their primary endpoints demonstrating significant blood pressure reductions. Learn more in our press release: $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results"
X Link 2025-03-10T11:05Z [---] followers, [----] engagements

"We will be sharing data from our pivotal Ph2 Advance-HTN trial in a late-breaking session at #ACC25 on Saturday March [--] from 1:45-1:55pm CT. Read our press release for additional details: $MLYS #hypertension #bloodpressure https://ir.mineralystx.com/news-events/press-releases/detail/63/mineralys-therapeutics-announces-data-from-the-phase-2 https://ir.mineralystx.com/news-events/press-releases/detail/63/mineralys-therapeutics-announces-data-from-the-phase-2"
X Link 2025-03-17T12:07Z [---] followers, [---] engagements

"Today we closed the sale of additional stock shares in our underwritten public offering bringing total gross proceeds to $201.2M. Funds will support the clinical development of lorundrostat R&D and pre-commercial activities. Learn more: $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/64/mineralys-therapeutics-announces-closing-of-underwriters https://ir.mineralystx.com/news-events/press-releases/detail/64/mineralys-therapeutics-announces-closing-of-underwriters"
X Link 2025-03-18T20:08Z [---] followers, [---] engagements

"Today we presented detailed results from the pivotal Advance-HTN trial at #ACC25 highlighting the impact of lorundrostat on blood pressure reduction in patients with confirmed uncontrolled or resistant #hypertension. Learn more about the findings: $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from"
X Link 2025-03-29T18:31Z [---] followers, [---] engagements

"@NEJM has published results from our Phase [--] Advance-HTN trial the first of two pivotal trials evaluating lorundrostat in patients with uncontrolled or resistant #hypertension. Learn more about the findings in our press release: #CardioRenalMetabolic https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal"
X Link 2025-04-24T12:37Z [---] followers, [--] engagements

"Today we reported financial results for the first quarter ending March [--] [----] and provided a corporate update. Learn more: $MLYS #Hypertension #CardioRenalMetabolic https://ir.mineralystx.com/news-events/press-releases/detail/70/mineralys-therapeutics-reports-first-quarter-2025-financial https://ir.mineralystx.com/news-events/press-releases/detail/70/mineralys-therapeutics-reports-first-quarter-2025-financial"
X Link 2025-05-12T20:08Z [---] followers, [---] engagements

"Today we presented detailed results from our pivotal Ph3 Launch-HTN trial at #ESH2025 reinforcing the promise of lorundrostat as a new treatment approach for aldosterone driven #hypertension. Read our press release to learn more: $MLYS #bloodpressure https://ir.mineralystx.com/news-events/press-releases/detail/72/mineralys-therapeutics-announces-late-breaking-presentation https://ir.mineralystx.com/news-events/press-releases/detail/72/mineralys-therapeutics-announces-late-breaking-presentation"
X Link 2025-05-24T12:05Z [---] followers, [---] engagements

"Today we announced positive topline results from our Phase [--] Explore-CKD trial evaluating the safety & efficacy of lorundrostat in subjects with #hypertension and comorbid chronic kidney disease (CKD). Read more $MLYS #bloodpressure #chronickidneydisease https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results"
X Link 2025-06-17T11:23Z [---] followers, [---] engagements

"Detailed results from the pivotal P3 Launch-HTN trial were published today in @JAMA_current reinforcing lorundrostats efficacy in a real-world setting. Read our press release to learn more: #bloodpressure $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american"
X Link 2025-06-30T17:11Z [---] followers, [---] engagements

"Today we reported financial results for the second quarter ending June [--] [----] and provided a corporate update. Learn more: #Hypertension #CKD #OSA #CardioRenalMetabolic #CVRM $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/76/mineralys-therapeutics-reports-second-quarter-2025 https://ir.mineralystx.com/news-events/press-releases/detail/76/mineralys-therapeutics-reports-second-quarter-2025"
X Link 2025-08-12T20:06Z [---] followers, [---] engagements

"Today we closed the sale of additional stock shares in our underwritten public offering bringing total gross proceeds to $287.5M. Funds will support clinical development of lorundrostat R&D and manufacturing & pre-commercial activities. Read: $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/79/mineralys-therapeutics-announces-closing-of-upsized-287-5 https://ir.mineralystx.com/news-events/press-releases/detail/79/mineralys-therapeutics-announces-closing-of-upsized-287-5"
X Link 2025-09-04T20:10Z [---] followers, [---] engagements

"Dr. Manish Saxena is presenting new subgroup analyses from our Launch-HTN trial of lorundrostat at the American Heart Association Hypertension Scientific Sessions. Details: #Hypertension25 #BloodPressure $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase"
X Link 2025-09-05T13:16Z [---] followers, [---] engagements

"In just [--] years Mineralys advanced #lorundrostat a potential first-in-class aldosterone synthase inhibitor from concept to pivotal published trials in #hypertension and is now preparing for a pre-NDA meeting in Q4 [----]. Learn more: #Innovation $MLYS https://www.thepharmaletter.com/pharmaceutical/q-a-with-jon-congleton-ceo-of-mineralys-therapeutics https://www.thepharmaletter.com/pharmaceutical/q-a-with-jon-congleton-ceo-of-mineralys-therapeutics"
X Link 2025-09-19T12:39Z [---] followers, [---] engagements

"Today we announced completion of enrollment in Explore-OSA our Ph [--] #clinicaltrial examining the efficacy safety & tolerability of lorundrostat in participants with #OSA and #hypertension. Topline results anticipated in Q1 [----]. Learn more here: $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/81/mineralys-therapeutics-completes-enrollment-in-phase-2 https://ir.mineralystx.com/news-events/press-releases/detail/81/mineralys-therapeutics-completes-enrollment-in-phase-2"
X Link 2025-09-30T20:57Z [---] followers, [---] engagements

"We will be presenting lorundrostat data from our Phase [--] Explore-CKD trial in a late-breaking session next month at @ASNKidney #KidneyWk on Friday November [--]. Read our press release for additional details: #Hypertension #CKD #ClinicalData $MLYS https://ir.mineralystx.com/news-events/press-releases/detail/82/mineralys-therapeutics-announces-late-breaking-presentation https://ir.mineralystx.com/news-events/press-releases/detail/82/mineralys-therapeutics-announces-late-breaking-presentation"
X Link 2025-10-21T12:04Z [---] followers, [---] engagements

"Data from the Phase [--] Launch-HTN trial of lorundrostat will be featured during a session tomorrow highlighting the most impactful #kidney research articles recently published in @JAMA_Network & @NEJM"
X Link 2025-11-06T21:23Z [---] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing